, Volume 1482, Issue 1, p 34
Date: 14 Dec 2013

Rabies vaccine

  • show all 0 hide

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Author Information

An event is serious (FDA MedWatch definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * requires intervention to prevent permanent impairment or damage

  • A 10-year-old boy developed erythema multiforme minor after receiving a rabies vaccine [Rabipur].

    The boy presented with a 5-day history of an erythematous eruption over his face and forearms; a mild burning sensation was associated with the lesions. Two weeks earlier, he had started receiving an IM rabies vaccine regimen [dosage not stated] after experiencing a dog bite on his leg. On examination, there were target lesions on his cheeks, along with dusky red papules and central necrosis over his forearms. The sites of the vaccine and dog bite were spared. Histopathologic examination found necrotic keratinocytes and basal cell layer degeneration, with evidence of early vesicle formation in the epidermis and oedema with moderate inflammation. He was diagnosed w ...